PMID: 3759249Jan 1, 1986Paper

Dosage of imipenem/cilastatin

Infection
P M Shah

Abstract

Imipenem/cilastatin was used for the treatment of 594 bacterial infections in 545 patients at a dosage of 1.5 g/day (n = 283), 2.0 g/day (n = 129), 3.0 g/day (n = 102), or 4 g/day (n = 11). The most common indications for therapy were nosocomial pneumonias followed by intraabdominal postoperative infections, and skin and soft tissue infections. Out of 1171 bacterial strains isolated from 932 patients, seven showed primary resistance to imipenem. The causative agent was eliminated in 87% of the patients. Treatment failed in 24 of the 594 patients. In 35 patients therapy was stopped because of side effects. The most frequent side effect was local irritation at the site of intravenous application.

References

May 1, 1978·Clinical Pharmacokinetics·N L Benowitz, W Meister
Jul 1, 1985·Reviews of Infectious Diseases·P M Shah
Oct 1, 1984·European Journal of Clinical Microbiology·I Braveny
Dec 1, 1982·Antimicrobial Agents and Chemotherapy·C Watanakunakorn, J C Tisone
Apr 2, 1960·Journal of the American Medical Association·F F FOLDESL R KOUKAL

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.